InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（10 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
10
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Hanson Kristopher, 首席执行官. Officer active across 3 companies, notably PhaseBio Pharmaceuticals Inc. Cumulatively, 17 filings have been recorded. Breakdown: 0 buy · 10 sells. Total volume traded: €572k. History available since 20 May 2021. The latest transaction was disclosed on 17 August 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Hanson Kristopher
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报17 总计
7,730 股0Voting Common StockSEC:0001789970-26-000014:0
5,103 股@ US$36.990.011% mcap10.9% 占其流量Voting Common StockSEC:0001789970-26-000012:1
2,147 股@ US$36.000.0045% mcap4.5% 占其流量Voting Common StockSEC:0001789970-26-000012:0
3,331 股@ US$37.260.0072% mcap7.2% 占其流量Voting Common StockSEC:0001789970-26-000012:4
4,776 股@ US$36.450.010% mcap10.0% 占其流量Voting Common StockSEC:0001789970-26-000012:3
10 股@ US$37.540.0000% mcap0.0% 占其流量Voting Common StockSEC:0001789970-26-000012:2
11 股@ US$37.960.0000% mcap0.0% 占其流量Voting Common StockSEC:0001789970-26-000012:5
1,130 股@ US$37.900.0025% mcap2.5% 占其流量Voting Common StockSEC:0001789970-26-000012:6
1,529 股@ US$26.800.0025% mcap83.4% 占其流量Voting Common StockSEC:0001789970-26-000006:0
73 股@ US$27.010.0001% mcap4.0% 占其流量Voting Common StockSEC:0001789970-26-000006:1
225 股@ US$27.490.0004% mcap12.6% 占其流量Voting Common StockSEC:0001789970-26-000006:2
7,730 股0Voting Common StockSEC:0001789970-26-000004:0
26,007 股@ US$17.9890.4% 占其流量Voting Common StockSEC:0001789970-26-000002:0
27,098 股0Voting Common StockSEC:0001789970-25-000008:0
4,831 股@ US$0.681337.3% 占其流量Common StockSEC:0001169245-22-000076:0
1,545 股@ US$2.0132.8% 占其流量Common StockSEC:0001169245-21-000126:0
1,088 股@ US$2.8029.9% 占其流量Common StockSEC:0001169245-21-000042:0
17 条申报中的 17 条
About Hanson Kristopher
Hanson Kristopher is Vice President, General Counsel and Chief Executive Officer. The 16 filings cover MapLight Therapeutics, Inc. and PhaseBio Pharmaceuticals Inc, with, in the recent sampled filings, 0 EUR of purchases and 572284 EUR of sales between 2021-05-24 and 2026-07-17. The top filings include 393724.1475435746 EUR on 2026-01-29, then 165013.9628862683 EUR, 151767.4808698661 EUR, 108201.7682103392 EUR, 67568.66521755354 EUR and 37417.95098614814 EUR on 2026-07-17.
